XML 51 R5.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Cash flows from operating activities:    
Net income $ 40,496 $ 13,596
Adjustments to reconcile net income to net cash from operating activities:    
Provision for doubtful accounts 722 108
Reserve for product returns (105) 210
Provision for notes receivable (3,319) 0
Amortization on patents and tooling 506 701
Amortization and depreciation 15,833 16,154
Amortization of debt issuance costs 81 81
Amortization of operating lease right-of-use assets 4,296  
Deferred income taxes 1,502 (9,108)
Stock-based compensation 14,721 9,670
Gain on notes receivable (6,931) 0
Acquired in-process research and development 850 0
Impairment of investment 605 0
Disposal of property and equipment 0 285
Changes in operating assets and liabilities:    
Accounts receivable (16,004) (15,145)
Inventory 2,012 (2,729)
Other current and non-current assets (6,813) (5,072)
Accounts payable, accrued expenses and other current liabilities (22,959) 28,472
Deferred revenue (1,153) (804)
Operating lease liabilities (681)  
Other liabilities 188 (1,441)
Cash flows from operating activities 23,847 34,978
Cash flows used in investing activities:    
Additions to property and equipment (10,660) (9,317)
Purchases of in-process research and development (850) 0
Issuances or purchases of notes receivable (26,074) 0
Receipt of payment on notes receivable 31,695 0
Cash flows used in investing activities (5,889) (9,317)
Cash flows from financing activities:    
Repayments of credit facility (3,000) (3,000)
Repurchases of common stock 0 (1)
Issuances of common stock from equity-based plans 3,304 5,254
Cash flows from financing activities 304 2,253
Net increase in cash and cash equivalents 18,262 27,914
Cash and cash equivalents at beginning of the period 146,061 96,329
Cash and cash equivalents at end of the period $ 164,323 $ 124,243